Dr. Justin Harmon

Dr. Justin Harmon
Justin D. Harmon, DO, FACOS, is a board-certified urologic surgeon, fellowship-trained in robotic and minimally invasive surgery for both benign and malignant conditions of the genitourinary tract. Dr. Harmon also employs state-of-the-art technology for the treatment of general urologic conditions. He takes pride in offering all therapies for benign prostatic hypertrophy and believes the best decision for treatment is based on the patient's full understanding of all treatments available matched against each treatment's side effect profile and patient desires. He received his medical degree from the Philadelphia College of Osteopathic Medicine. Dr. Harmon completed an internship and residency at Albert Einstein Medical Center in Philadelphia. He also completed a fellowship in laparoscopy and robotic urologic surgery at the Institut Mutualiste Montsouris in Paris, France. He currently directs the St. Mary Medical Center Robotics program. For multiple years, Dr. Harmon has been recognized nationally as a “Top Doc” in US news and World Report and a “Top Doctor in Urologic Surgery” by Philadelphia magazine.

Languages Spoken:

English and translation services available upon request

Medical School:

Philadelphia College of Osteopathic Medicine

Residency:

Albert Einstein Medical Center/Hahnemann University Hospital

Fellowship:

Robotics and laparoscopy at L'institut Mutualiste Montsouris, Paris, France

Undergraduate:

Villanova University

Locations

St. Mary Medical Center Langhorne, Pennsylvania

1201 Langhorne Newton RoadLanghorne, Pennsylvania, 19047United States

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only